All In Biotech

Drug Trial Radar · NCT06312748

Novel Approaches for Improving Vascular Function in Veterans With HFpEF

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

May 19, 2021

Primary completion

Sep 30, 2028

Study completion Sep 30, 2030

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
Collaborators
University of Utah
First posted
Mar 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF).

Conditions

  • Heart Failure With Preserved Ejection Fraction
  • Inflammation

Interventions

  • L-CitrullineDrug

    100 mg tablet

  • Placebo for L-CitrullineDrug

    L-Citrulline-matched Placebo tablet

  • BH4Drug

    10mg/kg

  • Placebo for BH4Drug

    BH4-matched Placebo

  • AtorvastatinDrug

    10 mg tablet

  • Placebo for AtorvastatinDrug

    Atorvastatin-matched Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Flow-mediated dilation (FMD)Time frame: Baseline, Day 90

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • VA Salt Lake City Health Care System, Salt Lake City, UT

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.